The way of SARS-CoV-2 vaccine development: success and challenges
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). To halt the pandemic, multiple SARS-CoV-2 vaccines have been developed and several have been allowed for emergency use and rollout worldwide. With novel SARS-CoV-2 var...
Enregistré dans:
Auteurs principaux: | Yetian Dong, Tong Dai, Bin Wang, Lei Zhang, Ling-hui Zeng, Jun Huang, Haiyan Yan, Long Zhang, Fangfang Zhou |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Publishing Group
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b5e9d063126f4948b1f5c2cde8276777 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in Deficiency
par: Maaz Jalil DO, et autres
Publié: (2021) -
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
par: Shipo Wu, et autres
Publié: (2020) -
Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
par: Lin Cheng, et autres
Publié: (2021) -
Racing for a SARS‐CoV‐2 vaccine
par: Özlem Türeci, et autres
Publié: (2021) -
Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge.
par: Antonio Muruato, et autres
Publié: (2021)